Mucoadhesive microorganism
AssigneeIntrexon Actobiotics NV
InventorsLothar STEIDLER, Klaas VANDENBROUCKE
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntrexon Actobiotics NV
InventorsLothar STEIDLER, Klaas VANDENBROUCKE
Estimating the term…
The present disclosure provides genetically modified microorganisms (e.g., bacteria or yeast) with enhanced mucin-binding and/or cell-adhesion properties. For example, the present disclosure provides bacteria exhibiting increased in vitro binding to Caco-2 cells, and increased in vitro binding to mucins. Such microorganisms (e.g., bacteria) can be used, e.g., to deliver bioactive polypeptides to the gastrointestinal tract of a mammalian subject. Modifying the microorganism in the described manner allows for the modulation of gastrointestinal retention and transit times for the microorganism (e.g., bacterium). Exemplary microorganisms (e.g., lactic acid bacteria, such as Lactococcus lactis) contain an exogenous nucleic acid encoding a fusion protein containing a cell-adherence polypeptide, such as CmbA, and a mucin-binding polypeptide, such as a trefoil factor (TFF), e.g., human TFF3. The current disclosure further provides method for making and using the described microorganisms (e.g., bacteria).
1-20. (canceled)
A recombinant lactic acid bacterium (LAB) comprising a first exogenous nucleic acid encoding a fusion protein comprising (a) an N-terminal trefoil factor (TFF) polypeptide and (b) a C-terminal cell adherence polypeptide that comprises a cell-wall anchoring domain.
A nucleic acid encoding a fusion protein, said nucleic acid comprising:
Dependencies are inferred from the claim text.